Hypertension is a foremost avertible risk factor for atherosclerosis and ischemic heart disease. Though modern and effective antihypertensive drugs are available, most patients persist with suboptimal blood pressure control. Most hypertensive patients want a combination of antihypertensive agents to achieve therapeutic goals. Likewise, recent guidelines endorse initiating treatment with combination therapy that provides greater antihypertensive power than the use of high doses of monotherapy. Moreover, it provides greater protection to target organs than monotherapy and reduced potential for side effects.
Merck has organized an interactive webinar on 16 th of July 2019 from 09:00 pm onwards. In this webinar, Dr. Arup Dasbiswas will talk about “Power and Promise of Beta-Blockers (BB) And Calcium-Channel Blockers (CCB) Combination”. We invite you to submit your questions which will be…
